Explore Partnering with Medtronic
Medtronic invites you to discover the opportunities in partnering with us to develop drug-device therapies for neurodegenerative diseases and other conditions of the central nervous system.
Why Partner with Medtronic
- Take advantage of Medtronic’s established track record of developing and commercializing combination drug-device products in the US and globally.
- Leverage the long and successful Medtronic history of delivering drugs to the intrathecal space using our implantable, programmable infusion systems, combined with our ability to navigate distinct areas of the brain, enabling delivery of drugs to where they are needed.
- Efficiently advance your molecule of interest by accessing Medtronic infusion systems for research and clinical trials.
- Receive development functional support and technical expertise from Medtronic.
- Expedite the pharmacokinetic/pharmacodynamic translational research and scale up/modeling for promising therapies by understanding their target engagement and potentially investigating their mechanism of action.
Opportunity Overview
Medtronic is interested in collaborating with pharmaceutical and biotech companies to develop new drug-device therapies for neurodegenerative diseases and other conditions of the central nervous system.
By partnering with us, you receive access to our infusion solutions, technical expertise, and functional support. The partnership allows you to leverage your expertise and resources, lead the clinical trial, and maintain all drug/biologic manufacturing operations.
Ultimately, you manufacture and sell the drug, and Medtronic sells and supports the device.
Partnerships Wanted
Please contact us if you are a company or individual with:
- Pharma/biotech development capabilities.
- An identified drug/biologic candidate:
- with a known delivery challenge and/or low blood brain barrier penetration.
- with demonstrated proof of concept in a relevant rodent model, if available.
- An interest in finding a drug delivery solution.
- Interest in funding a research collaboration for new therapy development with targeted drug delivery.
We are currently investigating targeted infusion to the brain, but are open to exploring other routes of continuous infusion including intravascular, subcutaneous, and drug delivery to peripheral organs such as the liver or kidney.
Next Steps
Learn about this partnership opportunity through the information and presentations on this site.
Then contact us to find out more and tell us about you.
See Important Safety Information on the market-released Medtronic products and therapies discussed in the presentations on this website: SynchroMed® II and DBS Therapy.